Actively Recruiting
Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid Tumors
Led by Qualigen Theraputics, Inc. · Updated on 2024-05-01
54
Participants Needed
4
Research Sites
160 weeks
Total Duration
On this page
Sponsors
Q
Qualigen Theraputics, Inc.
Lead Sponsor
T
Translational Drug Development
Collaborating Sponsor
AI-Summary
What this Trial Is About
Goal: learn about QN-302 in patients with solid tumors (metastatic, or advanced cancer). Main questions: * What does the study drug do to human body (Pharmacodynamics \[='PD'\]) * What does the body do to study drug (how processed in body (Pharmacokinetics \[='PK'\]) - Safety Study drug by intravenous infusion ('IV') once weekly for 3 weeks every 4-week 'cycle.' Study treatment continues as long as patient and their study doctor agree that study treatment is in the best interest of the patient.
CONDITIONS
Official Title
Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with histologically confirmed locally advanced or metastatic solid carcinomas
- Tumor progression after receiving all standard of care therapies or no approved therapy available
- Evaluable or measurable disease by RECIST 1.1
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
HonorHealth
Scottsdale, Arizona, United States, 85251
Actively Recruiting
2
Yale
New Haven, Connecticut, United States, 06520
Not Yet Recruiting
3
START Midwest
Grand Rapids, Michigan, United States, 49546
Actively Recruiting
4
MD Anderson Cancer Center
Houston, Texas, United States, 77002
Not Yet Recruiting
Research Team
T
Tariq Arshad, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here